[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GB202105276D0 - Delivery of gene therapy vectors - Google Patents

Delivery of gene therapy vectors

Info

Publication number
GB202105276D0
GB202105276D0 GBGB2105276.6A GB202105276A GB202105276D0 GB 202105276 D0 GB202105276 D0 GB 202105276D0 GB 202105276 A GB202105276 A GB 202105276A GB 202105276 D0 GB202105276 D0 GB 202105276D0
Authority
GB
United Kingdom
Prior art keywords
delivery
gene therapy
therapy vectors
vectors
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2105276.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Priority to GBGB2105276.6A priority Critical patent/GB202105276D0/en
Publication of GB202105276D0 publication Critical patent/GB202105276D0/en
Priority to PCT/GB2022/050928 priority patent/WO2022219332A1/en
Priority to EP22719987.4A priority patent/EP4323532A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18845—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2105276.6A 2021-04-13 2021-04-13 Delivery of gene therapy vectors Ceased GB202105276D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB2105276.6A GB202105276D0 (en) 2021-04-13 2021-04-13 Delivery of gene therapy vectors
PCT/GB2022/050928 WO2022219332A1 (en) 2021-04-13 2022-04-13 Delivery of gene therapy vectors
EP22719987.4A EP4323532A1 (en) 2021-04-13 2022-04-13 Delivery of gene therapy vectors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2105276.6A GB202105276D0 (en) 2021-04-13 2021-04-13 Delivery of gene therapy vectors

Publications (1)

Publication Number Publication Date
GB202105276D0 true GB202105276D0 (en) 2021-05-26

Family

ID=75949506

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2105276.6A Ceased GB202105276D0 (en) 2021-04-13 2021-04-13 Delivery of gene therapy vectors

Country Status (3)

Country Link
EP (1) EP4323532A1 (en)
GB (1) GB202105276D0 (en)
WO (1) WO2022219332A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
KR100807016B1 (en) * 2000-06-01 2008-02-25 가부시키가이샤 디나벡크 겐큐쇼 Pseudotype retroviral vectors comprising membrane proteins having hemagglutinin activity
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors

Also Published As

Publication number Publication date
WO2022219332A1 (en) 2022-10-20
EP4323532A1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
IL279918A (en) Gene therapy vectors for treatment of danon disease
SG11202107744SA (en) Gene therapy vectors for treatment of danon disease
IL289518A (en) Recombinant ad35 vectors and related gene therapy improvements
IL291488A (en) Gene therapy composition and treatment of right ventricular arrythmogenic cardiomyopathy
GB202003618D0 (en) Gene Therapy
GB202114972D0 (en) Gene therapy
IL307881A (en) Aavrh74 vectors for gene therapy of muscular dystrophies
IL307604A (en) Adenoviral gene therapy vectors
IL299380A (en) Improved adeno-associated virus gene therapy vectors
IL275951A (en) Immuno-evasive vectors and use for gene therapy
IL292717A (en) Treatment of hereditary angioedema with liver-specific gene therapy vectors
IL288193A (en) Gene therapy vectors for infantile malignant osteopetrosis
GB202105276D0 (en) Delivery of gene therapy vectors
IL290039A (en) Platelet-facilitated delivery of therapeutic compounds
IL306009A (en) Ocular delivery of therapeutic agents
IL299955A (en) GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
IL284411A (en) Targeted delivery of therapeutic molecules
ES3029738T3 (en) Sirna sequences targeting the expression of human genes jak1 for a therapeutic use
GB202206346D0 (en) Gene therapy
GB202010894D0 (en) Gene therapy
GB202003109D0 (en) Gene therapy
GB202002202D0 (en) Gene therapy
GB202004254D0 (en) Characterization of gene therapy vectors
IL286917A (en) Methods for scarless introduction of targeted modifications into targeting vectors
IL297656B1 (en) Gene therapy with dysferlin dual vectors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)